ATE323684T1 - Verfahren und zusammensetzungen unter verwendung von chinazolinonen - Google Patents

Verfahren und zusammensetzungen unter verwendung von chinazolinonen

Info

Publication number
ATE323684T1
ATE323684T1 AT01932769T AT01932769T ATE323684T1 AT E323684 T1 ATE323684 T1 AT E323684T1 AT 01932769 T AT01932769 T AT 01932769T AT 01932769 T AT01932769 T AT 01932769T AT E323684 T1 ATE323684 T1 AT E323684T1
Authority
AT
Austria
Prior art keywords
quinazolinones
compositions
methods
associatged
formulae
Prior art date
Application number
AT01932769T
Other languages
English (en)
Inventor
Jeffrey T Finer
Gustav Bergnes
Bainian Feng
Whitney W Smith
John C Chabala
David J Morgans Jr
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Application granted granted Critical
Publication of ATE323684T1 publication Critical patent/ATE323684T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Paints Or Removers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Fats And Perfumes (AREA)
AT01932769T 2000-06-21 2001-04-27 Verfahren und zusammensetzungen unter verwendung von chinazolinonen ATE323684T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21310400P 2000-06-21 2000-06-21
US09/699,047 US6545004B1 (en) 1999-10-27 2000-10-24 Methods and compositions utilizing quinazolinones

Publications (1)

Publication Number Publication Date
ATE323684T1 true ATE323684T1 (de) 2006-05-15

Family

ID=26907773

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01932769T ATE323684T1 (de) 2000-06-21 2001-04-27 Verfahren und zusammensetzungen unter verwendung von chinazolinonen

Country Status (23)

Country Link
US (7) US6545004B1 (de)
EP (2) EP1296959B1 (de)
JP (1) JP4854906B2 (de)
KR (1) KR100847788B1 (de)
CN (1) CN1229353C (de)
AT (1) ATE323684T1 (de)
AU (3) AU5927001A (de)
BR (1) BR0111898A (de)
CA (1) CA2413426C (de)
CY (1) CY1105070T1 (de)
CZ (1) CZ303007B6 (de)
DE (1) DE60118921T2 (de)
DK (1) DK1296959T3 (de)
ES (1) ES2262649T3 (de)
HU (1) HU229078B1 (de)
IL (1) IL153554A (de)
MX (1) MXPA02012627A (de)
NO (1) NO324440B1 (de)
NZ (1) NZ523233A (de)
PL (1) PL204525B1 (de)
PT (1) PT1296959E (de)
SI (1) SI1296959T1 (de)
WO (1) WO2001098278A1 (de)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965825A (en) 1981-11-03 1990-10-23 The Personalized Mass Media Corporation Signal processing apparatus and methods
US7831204B1 (en) 1981-11-03 2010-11-09 Personalized Media Communications, Llc Signal processing apparatus and methods
JP4831906B2 (ja) 1999-08-27 2011-12-07 ケモセントリックス， インコーポレイテッド Ｃｘｃｒ３機能を調節するための複素環式化合物および方法
US20070021493A1 (en) * 1999-09-16 2007-01-25 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US7671200B2 (en) * 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
ATE327224T1 (de) * 1999-10-27 2006-06-15 Cytokinetics Inc Chinazolinone benutzende verfahren und zusammenstellungen
MXPA03005152A (es) * 2000-12-11 2004-10-14 Tularik Inc Antogonista de cxcr3.
WO2002057244A1 (en) * 2001-01-19 2002-07-25 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
KR20040011549A (ko) 2001-06-22 2004-02-05 화이자 프로덕츠 인크. 저용해도 및(또는) 산-민감성 약물 및 중화된 산성중합체를 포함하는 제약 조성물
JP2005507876A (ja) * 2001-09-05 2005-03-24 ミナーバ バイオテクノロジーズ コーポレイション 癌を治療する組成物および方法
CA2465491A1 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2002366103A1 (en) * 2001-11-19 2003-06-10 Iconix Pharmaceuticals, Inc. Modulators of rho c activity
ATE480527T1 (de) * 2001-12-11 2010-09-15 Kyowa Hakko Kirin Co Ltd Thiadiazolinderivate zur krebsbehandlung
WO2003070701A2 (en) * 2002-02-15 2003-08-28 Cytokinetics, Inc. Syntheses of quinazolinones
ES2361403T3 (es) * 2002-03-07 2011-06-16 X-Ceptor Therapeutics, Inc. Moduladores de quinazolinona de receptores nucleares.
AU2003234733B2 (en) * 2002-04-17 2009-01-29 Cytokinetics, Inc. Compounds, compositions, and methods
US7214800B2 (en) * 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
CA2485148A1 (en) * 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
EP1513820A4 (de) * 2002-05-23 2006-09-13 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
WO2003106426A1 (en) * 2002-06-14 2003-12-24 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005533119A (ja) * 2002-07-17 2005-11-04 サイトキネティクス・インコーポレーテッド 化合物、組成物、及び方法
AU2003256805A1 (en) * 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
US20040048853A1 (en) * 2002-08-21 2004-03-11 Gustave Bergnes Compounds, compositions, and methods
EP1554265A4 (de) * 2002-09-13 2008-05-07 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
WO2004034972A2 (en) * 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
US7358262B2 (en) * 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
SE0300627D0 (sv) * 2003-03-07 2003-03-07 Astrazeneca Ab Novel fused heterocycles and uses therof
JP3947758B2 (ja) * 2003-03-07 2007-07-25 アストラゼネカ アクチボラグ 新規縮合ヘテロサイクル及びその使用
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
WO2004092123A2 (en) * 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
EP1622883A4 (de) * 2003-04-10 2008-04-02 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
CA2522594C (en) 2003-04-18 2012-01-24 Kyowa Hakko Kogyo Co., Ltd. Mitotic kinesin inhibitor
EP1620092A4 (de) * 2003-05-07 2008-04-16 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
EP1622878A4 (de) * 2003-05-15 2008-04-09 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
US7345046B2 (en) * 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
US20070276017A1 (en) * 2003-06-10 2007-11-29 Chikara Murakata Thiadiazoline Derivative
WO2004113335A2 (en) * 2003-06-20 2004-12-29 Chiron Corporation Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
AU2004264533B2 (en) * 2003-08-15 2009-01-22 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
JP2007507539A (ja) * 2003-10-06 2007-03-29 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
WO2005035512A1 (ja) * 2003-10-10 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. チアジアゾリン誘導体
JP2007510652A (ja) * 2003-11-03 2007-04-26 サイトキネティクス・インコーポレーテッド ピリミジン−４−オン化合物、組成物、および方法
EP1680420A4 (de) * 2003-11-07 2008-09-24 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
US7939539B2 (en) * 2003-11-25 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Quinazolinone compounds as anticancer agents
EP1692112A4 (de) 2003-12-08 2008-09-24 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
US7662581B1 (en) 2003-12-18 2010-02-16 Novartis Vaccines And Diagnostics, Inc. Eg5 co-crystals
JP2007518711A (ja) * 2003-12-19 2007-07-12 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
WO2005061518A1 (en) * 2003-12-19 2005-07-07 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2007517071A (ja) * 2003-12-19 2007-06-28 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
NZ551004A (en) 2004-04-02 2010-07-30 Prana Biotechnology Ltd Neurologically-active compounds
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
US7795448B2 (en) * 2004-05-06 2010-09-14 Cytokinetics, Incorporated Imidazoyl-benzamide anti-cancer agents
US7504413B2 (en) * 2004-05-06 2009-03-17 Cytokinetics, Inc. N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases
RS50670B (sr) * 2004-05-21 2010-06-30 Novartis Vaccines And Diagnostics Inc. Supstitucionisani derivati hinolina kao mitotički kinezinski inhibitori
US20050282834A1 (en) * 2004-06-09 2005-12-22 Fady Malik Compositions, devices and methods for treating cardiovascular disease
KR101170925B1 (ko) * 2004-06-18 2012-08-07 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 암 치료용 키네신 방추 단백질 (ｋｓｐ) 억제제로서의ｎ-(1-(1-벤질-4-페닐-1ｈ-이미다졸-2-일)-2,2-디메틸프로필)벤자미드 유도체 및 관련 화합물
US7375102B2 (en) 2004-06-28 2008-05-20 Amgen Sf, Llc Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
US7939538B2 (en) 2004-06-28 2011-05-10 Amgen Inc. Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
RU2007106552A (ru) * 2004-07-22 2008-08-27 Астразенека Аб (Se) Конденсированные пиримидоны, пригодные для лечения и предотвращения злокачественного новообразования
CN101027309B (zh) * 2004-08-18 2010-10-27 阿斯利康(瑞典)有限公司 所选择的稠合嘧啶酮的对映体和在治疗和预防癌症中的用途
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
EP1786265A4 (de) * 2004-08-30 2009-08-19 Smithkline Beecham Corp Neue zusammensetzungen und behandlungsverfahren
US20080064680A1 (en) * 2004-09-14 2008-03-13 Bamdad Cynthia C Methods for Diagnosis and Treatment of Cancer
JP2008517057A (ja) * 2004-10-19 2008-05-22 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド インドールおよびベンゾイミダゾール誘導体
US7449486B2 (en) * 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
US20100093767A1 (en) * 2004-12-03 2010-04-15 Takeda San Diego, Inc. Mitotic Kinase Inhibitors
NZ560320A (en) 2005-01-25 2011-02-25 Prolexys Pharmaceuticals Inc Quinoxaline derivatives as antitumor agents
US20070161644A1 (en) * 2005-01-25 2007-07-12 Stockwell Brent R Erastin analogs and uses thereof
WO2006101102A1 (ja) * 2005-03-22 2006-09-28 Kyowa Hakko Kogyo Co., Ltd. 固形腫瘍治療剤
EP1870404A4 (de) * 2005-03-22 2010-07-14 Kyowa Hakko Kirin Co Ltd Mittel zur behandlung eines hämatopoietischen tumors
DE102005024017A1 (de) * 2005-05-25 2006-11-30 Merck Patent Gmbh Chinazolinone
EP1908755A4 (de) * 2005-06-24 2009-06-24 Kyowa Hakko Kirin Co Ltd Therapeutisches mittel gegen restenose
TW200800951A (en) * 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
DE602006018176D1 (en) * 2005-09-26 2010-12-23 Merck Sharp & Dohme N-(4-oxo-3,4-dihydrochinazolin-2-yl)butanamide als androgenrezeptormodulatoren
DE102006002065B4 (de) * 2006-01-16 2007-11-29 Infineon Technologies Austria Ag Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
PE20080359A1 (es) 2006-04-19 2008-06-06 Novartis Ag Compuestos de benzoxazol y benzotiazol 6-0-sustituidos y metodos de inhibicion de la senalizacion de csf-1r
WO2007149476A2 (en) * 2006-06-19 2007-12-27 Trustees Of Columbia University In The City Of New York Assays for non-apoptotic cell death and uses thereof
US20090291442A1 (en) * 2006-07-27 2009-11-26 Smithkline Beecham Corporation Hspa1a as a marker for sensitivity to ksp inhibitors
JP5489333B2 (ja) 2006-09-22 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション 脂肪酸合成阻害剤を用いた治療の方法
WO2008041118A2 (en) * 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AU2007323998B2 (en) * 2006-11-13 2011-09-22 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors
AU2008205169B2 (en) * 2007-01-05 2012-02-02 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (Eg-5)
AR064777A1 (es) 2007-01-10 2009-04-22 Inst Di Reserche D Biolog Mole Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
ES2452349T3 (es) 2007-05-21 2014-04-01 Novartis Ag Inhibidores de CSF-1R, composiciones, y métodos de uso
AU2008268613A1 (en) 2007-06-22 2008-12-31 Arqule, Inc. Quinazolinone compounds and methods of use thereof
US20110123486A1 (en) * 2007-06-25 2011-05-26 Prolexys Pharmaceuticals, Inc. Methods of treating multiple myeloma and resistant cancers
EP3103791B1 (de) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino-derivate als histondeacetylase-hemmer
WO2009141541A2 (fr) * 2008-04-22 2009-11-26 Centre National De La Recherche Scientifique Nouvelles compositions inhibant la melanogenese et leurs utilisations
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2627178B1 (de) * 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Chinazolinonverbindungen als crth2-antagonisten
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2455456A1 (de) 2010-11-22 2012-05-23 Institut Curie Verwendung von Kinesininhibitoren bei der Behandlung von HIV-Infektion und Verfahren zu deren Abtastung
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
JP6207100B2 (ja) 2012-12-21 2017-10-04 ギリアード カリストガ エルエルシー イソキノリノンまたはキナゾリノンホスファチジルイノシトール３−キナーゼ阻害剤
NZ708864A (en) 2012-12-21 2016-09-30 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
ES2667173T3 (es) 2013-06-14 2018-05-09 Gilead Calistoga Llc Inhibidores de fosfatidilinositol 3-quinasa
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
WO2015051241A1 (en) * 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP4585268A3 (de) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Feste formen von isochinolinonderivaten, herstellungsverfahren, zusammensetzungen damit und verfahren zur verwendung davon
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2023203254A2 (en) * 2022-04-22 2023-10-26 Fundamental Pharma Gmbh Effective means to modulate nmda receptor-mediated toxicity
WO2024223617A1 (en) * 2023-04-24 2024-10-31 Fundamental Pharma Gmbh Effective means to modulate nmda receptor-mediated toxicity

Family Cites Families (199)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1053063A (de) 1963-05-18
US3320124A (en) 1964-07-20 1967-05-16 American Cyanamid Co Method for treating coccidiosis with quinazolinones
US3846549A (en) 1966-09-03 1974-11-05 Boehringer Sohn Ingelheim Pharmaceutical compositions containing an n-(1-bicyclic aryl-propyl -2)-n-phenyl-piperazine
BG16042A3 (bg) 1968-11-12 1972-05-20 Nans Ott Метод за получаване на нови 2(1н)-хиназолинони
US3962244A (en) 1971-01-23 1976-06-08 Hoechst Aktiengesellschaft Benzene sulfonyl ureas
US3740442A (en) 1972-01-14 1973-06-19 Sandoz Ag 2-isopropylaminobenzophenones in treating inflammation
US4011324A (en) * 1976-01-20 1977-03-08 Pfizer Inc. Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents
EP0009008A3 (de) 1978-09-08 1980-05-14 Ciba-Geigy Ag Cephalosporinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
US4281127A (en) 1979-07-09 1981-07-28 Hoffmann-La Roche Inc. Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives
EP0046953B1 (de) * 1980-08-30 1989-12-06 Hoechst Aktiengesellschaft Aminosäurederivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung
AU543928B2 (en) 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
EP0090068A1 (de) 1982-03-31 1983-10-05 Hans Wenner Münzautomat für Zeitungen, Zeitschriften, Lebensmittel oder andere Waren
GB8524663D0 (en) 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
JPH0625123B2 (ja) 1985-12-12 1994-04-06 大塚製薬株式会社 カルボスチリル誘導体−シクロデキストリン包接化合物
JPH0333118Y2 (de) 1986-02-20 1991-07-12
DE3609598A1 (de) 1986-03-21 1987-10-01 Hoechst Ag 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US5187167A (en) 1986-03-27 1993-02-16 Imperial Chemical Industries Plc Pharmaceutical compositions comprising quinazolin-4-one derivatives
US4670560A (en) * 1986-04-28 1987-06-02 Ortho Pharmaceutical Corporation Thienopyrimidine-2,4-dione derivatives and intermediates thereof
US4729996A (en) 1986-05-29 1988-03-08 Harbor Branch Oceanographic Institution, Inc. Antitumor compositions and their methods of use
DE3721855A1 (de) 1987-03-12 1988-09-22 Merck Patent Gmbh Aminosaeurederivate
GB8707053D0 (en) 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents
US4866084A (en) 1987-07-17 1989-09-12 Harbor Branch Oceanographic Institution, Inc. Topsentin compounds effective against viruses and certain tumors
US4808590A (en) 1987-07-17 1989-02-28 Harbor Branch Oceanographic Institution, Inc. Antiviral, antitumor and antifungal compositions and their methods of use
JPS6430768A (en) * 1987-07-28 1989-02-01 Toshiba Corp Thermal head
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US4857530A (en) 1987-11-03 1989-08-15 Warner-Lambert Company Substituted quinazolinones as anticancer agents
ATE113953T1 (de) 1988-05-10 1994-11-15 Ici Plc Cephalosporine, verfahren zu ihrer herstellung und pharmazeutische präparate.
GB8820129D0 (en) 1988-08-24 1988-09-28 Schering Agrochemicals Ltd Fungicides
GB8827820D0 (en) 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
GB8829296D0 (en) 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
US4970226A (en) 1989-10-03 1990-11-13 Harbor Branch Oceanographic Institution, Inc. Bis-indole imidazole compounds which are useful antitumor and antimicrobial agents
US5032598A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
CA2075627A1 (en) 1990-02-13 1991-08-14 William J. Greenlee Angiotensin ii antagonists incorporating a substituted benzyl element
US5264439A (en) 1990-02-13 1993-11-23 Merck & Co., Inc. Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists incorporating a substituted benzyl element
IL98167A0 (en) 1990-05-30 1992-06-21 Ici Plc Anti-tumour quinazoline derivatives,processes for their preparation and pharmaceutical compositions comprising them
FR2665159B1 (fr) * 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
EP0481614A1 (de) 1990-10-01 1992-04-22 Merck & Co. Inc. Substituierte Pyridopyrimidinone und verwandte Heterocyclen als Angiotensin-II-Antagoniste
NL9100023A (nl) * 1991-01-09 1992-08-03 Crown Gear Bv Slijpschijf voor het vervaardigen van kroonwielen, alsmede werkwijze voor het vervaardigen van een dergelijke slijpschijf.
GB9105771D0 (en) 1991-03-19 1991-05-01 Cancer Res Inst Royal Anti-cancer compounds
US5162325A (en) 1991-05-07 1992-11-10 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted benzyl element
US5714493A (en) 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5316906A (en) 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
US5256667A (en) 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
CA2079982A1 (en) 1991-10-07 1993-04-08 Stephen E. De Laszlo Substituted pyrazino (2,3-d)-pyrimidinones as angiotensin ii antagonists
GB9125515D0 (en) 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
US5204354A (en) 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
RU2104279C1 (ru) 1992-03-12 1998-02-10 Смитклайн Бичам Плс Конденсированное индольное производное или его фармацевтически приемлемая соль, фармацевтическая композиция, проявляющая активность антагониста 5-нт*004-рецептора
GB9205907D0 (en) 1992-03-18 1992-04-29 Cancer Res Inst Royal Anti-cancer compounds
US5430148A (en) 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
WO1993023404A1 (en) 1992-05-19 1993-11-25 Immunopharmaceutics, Inc. Compounds that modulate endothelin activity
GB9220571D0 (en) 1992-09-30 1992-11-11 Ici Plc Quinazoline derivatives
JPH06148835A (ja) 1992-11-04 1994-05-27 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料およびその処理方法
US5817662A (en) 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5780476A (en) 1992-11-16 1998-07-14 Cell Therapeutics, Inc. Hydroxyl-containing xanthine compounds
WO1994015605A1 (en) 1993-01-14 1994-07-21 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
AU6092794A (en) 1993-01-19 1994-08-15 Cell Therapeutics, Inc. Oxime-substituted therapeutic compounds
US5574057A (en) 1993-02-03 1996-11-12 University Of Utah Research Foundation Naamidine A extracted from sea sponges and methods for its use as an anti-tumor agent
US5401745A (en) 1993-03-19 1995-03-28 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5837703A (en) 1993-03-31 1998-11-17 Cell Therapeutics, Inc. Amino-alcohol substituted cyclic compounds
US5342944A (en) 1993-07-19 1994-08-30 American Cyanamid Company Process for the preparation of 2-alkyl-3,5,6,7- or 8-substituted-4(3H)-quinazolinones
US20020198326A1 (en) 1993-11-12 2002-12-26 Taizo Aoyama Polyolefin resin composition
US5589489A (en) 1993-12-15 1996-12-31 Zeneca Limited Cyclic amide derivatives for treating asthma
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
CA2113229C (en) 1994-01-11 1999-04-20 Mark Pines Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
WO1995019171A1 (en) 1994-01-14 1995-07-20 Cell Therapeutics, Inc. Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
WO1995022546A1 (en) 1994-02-18 1995-08-24 Cell Therapeutics, Inc. Intracellular signalling mediators
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5801182A (en) 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5756502A (en) 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
JPH09165385A (ja) * 1994-08-26 1997-06-24 Kyowa Hakko Kogyo Co Ltd キナゾリン誘導体
IL110831A (en) 1994-08-31 1998-12-27 Hadasit Med Res Service Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis
US5891879A (en) 1994-08-31 1999-04-06 Hadasit Medical Research Services & Development Co., Inc. Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
IL112125A (en) 1994-12-22 1998-02-08 Hadasit Med Res Service Quinazolinone-containing pharmaceutical compositions
DE69616993T2 (de) 1995-03-14 2002-07-04 Novartis Ag, Basel Trisubstituierte phenyl derivate
WO1996028444A1 (en) 1995-03-15 1996-09-19 Pfizer Inc. 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS
US5753664A (en) 1995-03-16 1998-05-19 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
EP0735143B1 (de) * 1995-03-28 1998-11-18 Tanabe Seiyaku Co., Ltd. Verfahren zur Herstellung von D-Aminosäuren
WO1996039403A1 (en) 1995-06-05 1996-12-12 Neurogen Corporation 1-(n'-(arylalkylaminoalkyl)) aminoisoindoles as dopamine receptor ligands
US6245768B1 (en) 1995-06-05 2001-06-12 Neurogen Corporation 1-(N′-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligands
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CN1090621C (zh) 1995-08-30 2002-09-11 株式会社大冢制药厂 制备喹唑啉－4－酮衍生物的方法
AU4858596A (en) 1995-09-15 1997-04-01 Torrey Pines Institute For Molecular Studies Synthesis of quinazolinone libraries
US5783577A (en) 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
DE19546918A1 (de) 1995-12-15 1997-06-19 Bayer Ag Bicyclische Heterocyclen
DE19615262A1 (de) 1996-04-18 1997-10-23 Bayer Ag Heteroverknüpfte Phenylglycinolamide
KR100375155B1 (ko) 1996-05-15 2003-08-19 화이자 인코포레이티드 신규한2,3-이치환된-4(3에이치)-퀴나졸리논
US6008010A (en) 1996-11-01 1999-12-28 University Of Pittsburgh Method and apparatus for holding cells
BR9714222A (pt) * 1996-12-17 2000-04-18 Du Pont Método para o controle de doenças de plantas
US6028075A (en) 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
US5852024A (en) 1997-02-11 1998-12-22 Hadasit Treatment and prevention of adhesions
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
US5948775A (en) 1997-03-19 1999-09-07 American Home Products Corporation 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones
US6627755B1 (en) 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
ES2245015T3 (es) 1997-06-09 2005-12-16 Pfizer Products Inc. Quinazolin-4-onas como antagonistas de ampa.
US6060479A (en) 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
US6251902B1 (en) 1997-06-25 2001-06-26 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
US5939421A (en) 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
JP2934628B2 (ja) * 1997-08-21 1999-08-16 株式会社資生堂 キナゾリノン誘導体及び養毛剤、皮膚外用剤
US5972929A (en) 1997-08-21 1999-10-26 Shiseido Co., Ltd. Quinazolinone derivative, hair growth promoter and external composition for skin using the same
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US6639051B2 (en) 1997-10-20 2003-10-28 Curis, Inc. Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
JP2002500190A (ja) 1998-01-08 2002-01-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 海洋海綿から誘導されるキネシンモーターモジュレーター
US6214879B1 (en) 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
ATE286032T1 (de) 1998-04-23 2005-01-15 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
WO2000000491A1 (en) 1998-06-29 2000-01-06 The Regents Of The University Of California Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents
WO2000007017A2 (en) 1998-07-27 2000-02-10 President And Fellows Of Harvard College Method of high-throughput screening
US6596497B1 (en) * 1999-03-17 2003-07-22 New York Blood Center, Inc. Screening of antiviral compounds targeted to the HIV-1 gp41 core structure
GB9911071D0 (en) 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
US6197488B1 (en) 1999-07-21 2001-03-06 Eastman Kodak Company Color photographic element containing a coupler releasing derivative with at least three heteroatoms with specific hydrophobicity
JP4831906B2 (ja) 1999-08-27 2011-12-07 ケモセントリックス， インコーポレイテッド Ｃｘｃｒ３機能を調節するための複素環式化合物および方法
US6156758A (en) 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
AU780846B2 (en) 1999-09-16 2005-04-21 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
CA2385921A1 (en) 1999-09-28 2001-04-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Quinazolinones
CA2385918A1 (en) 1999-09-28 2001-04-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Quinazolinones
EP1216243A1 (de) 1999-10-01 2002-06-26 Advanced Medicine, Inc. Quinazolinone und analoga und ihre verwendung als lokalanästhetika
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
ATE327224T1 (de) 1999-10-27 2006-06-15 Cytokinetics Inc Chinazolinone benutzende verfahren und zusammenstellungen
US6476041B1 (en) * 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6380205B1 (en) 1999-10-29 2002-04-30 Merck & Co., Inc. 2-cyclohexyl quinazoline NMDA/NR2B antagonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6495561B2 (en) * 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
JP2003520355A (ja) 2000-01-13 2003-07-02 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 原ソースから離れた後の圧縮コンテンツ保護
ES2159488B1 (es) 2000-03-07 2002-04-16 Uriach & Cia Sa J Procedimiento para la preparacion de derivados de pirimidona con actividad antifungica.
US20020082268A1 (en) 2000-03-20 2002-06-27 Yun Gao Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
US6613798B1 (en) 2000-03-30 2003-09-02 Curis, Inc. Small organic molecule regulators of cell proliferation
CA2404413C (en) 2000-03-30 2015-10-20 Curis, Inc. Small organic molecule regulators of cell proliferation
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
ES2788383T3 (es) 2000-04-25 2020-10-21 Icos Corp Inhibidores de delta fosfatidilo-inositol 3-quinasa humana
AU7526901A (en) 2000-06-09 2001-12-24 Gilead Sciences Inc Liposomal benzoquinazoline thymidylate synthase inhibitor formulations
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
EP1174430A1 (de) 2000-07-20 2002-01-23 Universität Konstanz Verfahren zur Herstellung von Heteroringen unter Verwendung von C1-Bausteinen
CZ2003243A3 (cs) 2000-07-26 2003-09-17 Smithkline Beecham P. L. C. Aminopiperidinové chinoliny a jejich azaisosterické analogy s antibakteriální aktivitou
WO2002009713A2 (de) 2000-08-01 2002-02-07 Bayer Aktiengesellschaft Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
JP5000068B2 (ja) 2000-08-11 2012-08-15 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド チロシンキナーゼのインヒビターとして有用な複素環化合物
US20020165221A1 (en) 2000-10-13 2002-11-07 Baxter Anthony David Mediators of hedgehog signaling pathways, compositions and uses related thereto
ES2623711T3 (es) 2000-10-13 2017-07-12 Curis, Inc. Antagonistas de hedgehog, procedimientos y usos relacionados con los mismos
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
MXPA03005152A (es) 2000-12-11 2004-10-14 Tularik Inc Antogonista de cxcr3.
DE60208186T2 (de) * 2001-04-09 2006-08-24 Ortho-Mcneil Pharmaceutical Research Inc. Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrin-vermittelten erkrankungen
US7365199B2 (en) * 2001-04-20 2008-04-29 Fujifilm Corporation Dye-forming coupler, silver halide photographic light-sensitive material, and azomethine dye compound
US20030096813A1 (en) * 2001-04-20 2003-05-22 Jingrong Cao Compositions useful as inhibitors of GSK-3
JPWO2002094790A1 (ja) 2001-05-23 2004-09-09 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
US6936842B2 (en) * 2001-06-27 2005-08-30 Applied Materials, Inc. Method and apparatus for process monitoring
US20030220338A1 (en) 2001-07-16 2003-11-27 Watkins Will J. Fungal efflux pump inhibitors
US6596723B1 (en) * 2001-07-16 2003-07-22 Essential Therapeutics, Inc. Fungal efflux pump inhibitors
WO2003007888A2 (en) * 2001-07-20 2003-01-30 Adipogenix, Inc. Fat accumulation-modulating compounds
JP2005507876A (ja) 2001-09-05 2005-03-24 ミナーバ バイオテクノロジーズ コーポレイション 癌を治療する組成物および方法
EP1434584A2 (de) 2001-09-05 2004-07-07 Minerva Biotechnologies Corporation Zusammensetzungen und verfahren für die krebsbehandlung
NZ533057A (en) 2001-10-26 2005-11-25 Angeletti P Ist Richerche Bio N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
EP1441734B1 (de) 2001-10-26 2007-02-28 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
CA2465491A1 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2002366103A1 (en) 2001-11-19 2003-06-10 Iconix Pharmaceuticals, Inc. Modulators of rho c activity
AU2002346471A1 (en) 2001-11-20 2003-06-10 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
US20050107404A1 (en) 2001-12-06 2005-05-19 Fraley Mark E. Mitotic kinesin inhibitors
US7378411B2 (en) 2001-12-06 2008-05-27 Merck & Co., Inc. Substituted thienopyrimidinones as a mitotic kinesin inhibitor
US7262187B2 (en) 2001-12-06 2007-08-28 Merck & Co., Inc. Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor
AU2002363960B2 (en) 2001-12-06 2008-07-10 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
AU2002364128B2 (en) 2001-12-06 2008-03-06 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
MXPA03008967A (es) 2002-02-01 2004-02-12 King Pharmaceuticals Res & Dev Antagonistas receptores de 8-heteroarilo xantina adenosina a-2b.
WO2003070701A2 (en) 2002-02-15 2003-08-28 Cytokinetics, Inc. Syntheses of quinazolinones
US20030158188A1 (en) * 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
ES2361403T3 (es) 2002-03-07 2011-06-16 X-Ceptor Therapeutics, Inc. Moduladores de quinazolinona de receptores nucleares.
EP1492487B1 (de) 2002-03-08 2009-11-11 Merck & Co., Inc. Mitotische kinesin-hemmer
US6900219B2 (en) 2002-04-04 2005-05-31 Cv Therapeutics, Inc. ABCA-1 elevating compounds
CA2485148A1 (en) 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
US7214800B2 (en) 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005530806A (ja) 2002-05-23 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害薬
WO2004039774A2 (en) 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1513820A4 (de) 2002-05-23 2006-09-13 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
ES2282647T3 (es) 2002-06-14 2007-10-16 MERCK & CO., INC. Inhibidores de cinesina mitotica.
WO2003106426A1 (en) 2002-06-14 2003-12-24 Cytokinetics, Inc. Compounds, compositions, and methods
MXPA04012642A (es) 2002-06-14 2005-03-23 Merck & Co Inc Inhibidores de la cinesina mitotica.
AU2003238157A1 (en) 2002-06-18 2003-12-31 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
CA2489562A1 (en) 2002-07-08 2004-01-15 Merck & Co., Inc. Mitotic kinesin binding site
US20040092561A1 (en) * 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
JP2006500327A (ja) 2002-07-10 2006-01-05 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 精子の運動性を増大させるための化合物の使用
AU2003256805A1 (en) 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
US20040048853A1 (en) 2002-08-21 2004-03-11 Gustave Bergnes Compounds, compositions, and methods
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
AU2003263323A1 (en) 2002-09-07 2004-03-29 Celltech R And D Limited Quinazolinone derivatives
WO2004034972A2 (en) 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
EP1585522B1 (de) 2002-12-23 2010-11-17 Icagen, Inc. Quinazolinone als kaliumkanalmodulatoren
WO2004064741A2 (en) 2003-01-17 2004-08-05 Cytokinetics Inc. Compounds, compositions, and methods
JP3947758B2 (ja) 2003-03-07 2007-07-25 アストラゼネカ アクチボラグ 新規縮合ヘテロサイクル及びその使用
US7022850B2 (en) 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
JP4977837B2 (ja) * 2003-09-10 2012-07-18 アイカジェン， インコーポレイテッド カリウム・チャネル・モジュレーターとしての縮合環式複素環
US7939539B2 (en) * 2003-11-25 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Quinazolinone compounds as anticancer agents
US20050152940A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20050282834A1 (en) 2004-06-09 2005-12-22 Fady Malik Compositions, devices and methods for treating cardiovascular disease

Also Published As

Publication number Publication date
HUP0301201A3 (en) 2004-03-29
IL153554A0 (en) 2003-07-06
DE60118921T2 (de) 2006-11-23
ES2262649T3 (es) 2006-12-01
KR20030047903A (ko) 2003-06-18
HK1053837A1 (en) 2003-11-07
HU229078B1 (en) 2013-07-29
DE60118921D1 (de) 2006-05-24
EP1296959A1 (de) 2003-04-02
WO2001098278A1 (en) 2001-12-27
CZ20024178A3 (cs) 2003-05-14
US6545004B1 (en) 2003-04-08
EP1707563A3 (de) 2007-06-06
MXPA02012627A (es) 2003-09-25
CA2413426A1 (en) 2001-12-27
JP4854906B2 (ja) 2012-01-18
US20040254203A1 (en) 2004-12-16
JP2004501140A (ja) 2004-01-15
NO20026172L (no) 2003-02-20
AU5927001A (en) 2002-01-02
PL358412A1 (en) 2004-08-09
SI1296959T1 (sl) 2007-02-28
NO20026172D0 (no) 2002-12-20
EP1707563A2 (de) 2006-10-04
US6562831B1 (en) 2003-05-13
US6831085B1 (en) 2004-12-14
HUP0301201A2 (hu) 2003-12-29
EP1296959B1 (de) 2006-04-19
CN1229353C (zh) 2005-11-30
NZ523233A (en) 2004-10-29
DK1296959T3 (da) 2006-07-31
US6630479B1 (en) 2003-10-07
US20040023996A1 (en) 2004-02-05
BR0111898A (pt) 2003-05-13
CN1437585A (zh) 2003-08-20
CA2413426C (en) 2011-01-04
NO324440B1 (no) 2007-10-15
IL153554A (en) 2009-09-01
AU2006236024A1 (en) 2006-12-07
US7105668B1 (en) 2006-09-12
PT1296959E (pt) 2006-07-31
CY1105070T1 (el) 2009-11-04
KR100847788B1 (ko) 2008-07-23
AU2001259270B2 (en) 2006-08-24
PL204525B1 (pl) 2010-01-29
US7294634B2 (en) 2007-11-13
CZ303007B6 (cs) 2012-02-22

Similar Documents

Publication Publication Date Title
DE60118921D1 (de) Verfahren und Zusammensetzungen unter Verwendung von Chinazolinonen
ATE327224T1 (de) Chinazolinone benutzende verfahren und zusammenstellungen
SE9900100D0 (sv) New compounds
WO2004018058A3 (en) Compounds, compositions, and methods
MY140767A (en) Compounds, methods and compositions
MY140169A (en) Compounds, compositions, and methods
WO2004009036A3 (en) Compounds compositions and methods
WO2004034972A3 (en) Compounds, compositions, and methods
WO2004064741A3 (en) Compounds, compositions, and methods
ATE534649T1 (de) Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
ATE423110T1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
WO2004032840A3 (en) Compounds, compositions, and methods
WO2005046588A3 (en) Compounds, compositions, and methods
WO2005042697A3 (en) Compounds, compositions and methods
WO2004032879A3 (en) Compounds, compositions, and methods
WO2004024086A3 (en) Compounds, compositions and methods
WO2005062847A3 (en) Compounds, compositions and methods
ATE314066T1 (de) Verwendung von buprenorphin zur therapie der harninkontinenz
WO2005041888A3 (en) Pyrimidin-4-one compounds, compositions and methods
DE502005005474D1 (de) Verwendung von speziellen formylierten chinoliniumderivaten in kombination mit aminosubtituierten pyrimidinderivaten und mindestens einem weiteren primären oder sekundären, aromatischen amin
DE60235589D1 (de) Wortmannin-Analoge und Verfahren zu deren Verwendung
HK1068212A (en) Compounds, methods and compositions

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1296959

Country of ref document: EP